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(TASC) C and D lesions of the superficial femoral artery (SFA) are supragenicular bypass grafting
or the less invasive remote endarterectomy (RSFAE). This trial compares the patency rates of
both techniques.
Design: Randomized, multicenter trial.
Materials and methods: 116 patients were randomized to RSFAE (nZ 61) and supragenicular
bypass surgery (nZ 55). Indications for surgery were claudication (nZ 77), rest pain
(nZ 21), or tissue loss (nZ 18).
Results: Median hospital stay was 4 days in the RSFAE group compared with 6 days in the bypass
group (pZ 0.004). Primary patency after 1-year follow-up was 61% for RSFAE and 73% for
bypass (pZ 0.094). Secondary patency was 79% for both groups. Subdividing between venous
(nZ 25) and prosthetic grafts (nZ 30) shows a primary patency of 89% and 63% respectively at
1-year follow-up (pZ 0.086).
Conclusion: RSFAE is a minimally invasive adjunct in the treatment of TASC C and D lesions of
the SFA, with shorter admittance and a comparable secondary patency rate to bypass. Thez, MD, Department of Vascular Surgery, Sint Antonius Hospital, P.O. Box 2500, 3430 EM Nieuwegein,
1; fax: þ31 306036578.
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a sufficient saphenous vein available.
This study is registered with ClinicalTrials.gov, number NCT00566436.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Different treatment modalities exist for Trans-Atlantic
Inter-Society Consensus1 (TASC) C and D lesions of the
superficial femoral artery (SFA). Every possible procedure
still has a significant reobstruction rate, which might result
in major lower limb amputation. Patency rates for percu-
taneous transluminal angioplasty (PTA) are discouraging.2
The use of additional stents has not improved these
results.3 Subintimal angioplasty is only performed with
acceptable patency rates in specialized centres.4
The most implemented and established procedure for
treatment of TASC C and D SFA obstructions is prosthetic or
venous bypass grafting, with patency rates of 39e57% for
prosthetic and 70e77% for venous bypass grafts.5e10
An alternative surgical technique has been developed
since 1994, the remote SFA endarterectomy (RSFAE).11,12
Patency rates of retrospective studies so far are promising,
with reported patency rates of 61e69% at 18e33 months.13
Furthermore, this procedure might offer several advan-
tages over bypass surgery, including shorter hospital stay
and fewer wound-related problems. To compare patency
rates of both surgical techniques, the randomized Remote
Endarterectomy Versus Above-knee bypass Surgery (REVAS)
trial was performed and short-term results are reported in
this article.
Materials and Methods
Study design
Study inclusion was between October 2004 and March 2007
in 1 university medical centre and 3 major teaching hospi-
tals. The randomization of the study is closed.
Included were consecutive patients presenting with
severe claudication, critical ischemia, or tissue loss (Ruth-
erford category 3e5)14 with a TASC C or D lesion of the SFA
and a patent popliteal P1 segment with at least 1 crural
runoff vessel. Only patients with chronic (>6 months)
complaints originating from atherosclerotic disease were
included.
Exclusion criteria were previous surgery or PTA with
additional stent placement of the target SFA and a SFA
diameter <4 mm.15 Heavily calcified vessels were not
excluded.
The treating vascular surgeon established the feasibility
of patients by checking the inclusion criteria. All indications
for revascularization were discussed in a multidisciplinary
team. Randomization was done at a central telephone
number, using sealed envelopes, in a permuted-block
sequence and balanced by participating centre. The
vascular surgeons were completely blinded on the sequence
of the randomization list. Patients were randomly assigned
to RSFAE or bypass with the ipsilateral saphenous vein.When the saphenous vein was not available or, when the
vein was of inadequate diameter, patients received a poly-
tetrafluoroethylene graft (PTFE bypass, W.L. Gore and
Associates, Inc., Flagstaff, AZ, USA).
The primary endpoint was the primary patency at 5
years. This article is an interim report, presenting short-
term results. Secondary endpoints were assisted primary
patency, secondary patency, limb-salvage, operation time,
postoperative complications, and hospital stay. Moreover,
possible prognostic factors concerning the primary patency
for both study arms will be analysed.
Patency is defined in conformity with the guidelines by
Rutherford et al.14 Primary patency is defined as uninter-
rupted patency without any procedures performed on the
treated segment. Assisted primary patency is the situation
in which patency was never lost but maintained by
prophylactic intervention. Secondary patency is restored
patency after occlusion, excluding redo or secondary
reconstruction operations that do not preserve most of the
original graft and at least 1 anastomosis.
Patency was determined by duplex ultrasound imaging.
A stenosis was considered significant if the peak systolic
velocity ratio exceeded 2.5 or the end-diastolic velocity
was higher than 60 cm/s.14
The medical ethics board of all participating hospitals
approved the study protocol. Informed consent was
obtained from all patients. This study is registered with
ClinicalTrials.gov, number NCT00566436.
Procedure
The preoperative evaluation consisted of medical history,
including risk factors; physical examination, including
peripheral pulses; ankle-brachial indices (ABIs), and
a treadmill test; color flow duplex ultrasound scanning; and
a magnetic resonance angiography (MRA), including crural
outflow and mapping of the ipsilateral greater saphenous
vein. The decision whether the greater saphenous vein was
applicable for grafting (diameter >3.0 mm)16 was made
during preoperative venous mapping using a tourniquet and
also assessed during surgery.
General
Vascular surgeons who had executed RSFAE previously in at
least 10 patients, and venous and prosthetic bypasses in 30
patients, performed all the surgical procedures. Ceftriax-
one (2 g) was administered intravenously, general or
regional anesthesia was used, and the patient underwent
systemic heparinization (5000 IE) before the femoral artery
was excluded from circulation.
RSFAE
Exposure of the common femoral, superficial femoral, and
profunda femoris arteries through a single groin incision.
Arteriotomy in the proximal SFA followed by dissection of
70 S.S. Gisbertz et al.the intima core beyond the occluded SFA segment using the
Vollmar ring stripper (Vollmar Dissector, Aesculap, South
San Francisco, CA, USA) under fluoroscopic guidance. The
ring stripper is exchanged for a Mollring Cutter (Mollring
Cutter, LeMaitre Vascular, Inc., Burlington, MA, USA), with
which transection of intima core is done remote from the
site of entry (Fig. 1). After removal of the intima core, the
transection zone is passed by a 0.035-inch. Terumo guide-
wire (Terumo, Terumo Corporation, Tokyo, Japan) and
secured with an aSpire stent (aSpire stent, LeMaitre
Vascular, Inc., Burlington, MA, USA). This stent has a PTFE-
covered nitinol framework with a DNA helical structure,
offering the possibility of preserving collaterals. It is flex-
ible and has high radial strength that makes it eligible for
use in proximity of the knee joint with its torsion and
flexion forces. By means of a completion arteriography,
eventual distal thromboemboli can be verified and embo-
lectomy performed if necessary. A common femoral and
profunda femoris endarterectomy can be performed, and
the arteriotomy may be closed with or without patch.
Bypass surgery
Vertical groin and supragenicular incisions, implantation of
a deep-tunnelled reversed saphenous vein or PTFE graft
with end-to-side anastomoses.
In case of multilevel disease a simultaneous procedure
could be performed, such as PTA or endarterectomy of
iliac, common femoral or popliteal arteries.
All patients were given antiplatelet therapy before the
procedure consisting of acetylsalicylic acid (100 mg daily)
or coumarin derivatives on indication. This regimen was
continued after the operation.
Follow-up
Follow-up was scheduled at 3, 6, 12, 18, and 24 months and
annually thereafter. Routine surveillance consisted of
history, physical examination, ABIs, and duplex ultrasound
scanning, with additional angiography or MRA as indicated.
In the first year after the procedure, even asymptomatic
restenoses were treated because previous studies haveFigure 1 The Mollring cutter is shown transecting the intima
core under fluoroscopic guidance.shown that revision of early restenoses will improve long-
term patency rates.15
Statistical analysis
Based on a primary patency rate of 70% at 2 years and
accepting a difference of 25%, it was calculated that the
study needed to include 116 patients to obtain sufficient
statistical power (aZ 0.05, two-sided; powerZ 0.8). The
study was planned as a non-inferiority trial. Data were
analysed based on intention to treat. Patency rates were
calculated with KaplaneMeier life-table estimates. Multi-
variate analysis was performed in both study arms sepa-
rately, to identify prognostic factors influencing primary
patency depending on operative strategy. Multivariate
analysis was performed using the Cox hazard regression
method. The univariate analysis, including all baseline
parameters (Table 1), served as the basis for the multivar-
iate Cox hazard regression model. Variables showing asso-
ciation (p< 0.10) with the primary patency in univariate
analysis were included in themultivariate analysis. Age, sex,
indication for operation and outflow were included in all
multivariate analyses. Results are presented as hazard ratio
with exact 95% confidence interval (95% CI). A log-rank test,
ManneWhitney U test, or c2 test was used as indicated to
compare both groups. A value of p< 0.05 was considered
statistically significant. Statistical analysis was performed
with SPSS 15.0 software (SPSS, Inc., Chicago, IL, USA).
Results
357 consecutive patients with a TASC C or D lesion of the
SFA were assessed for eligibility. 118 patients were included
and randomly assigned to RSFAE or bypass. Two patients
were excluded from the bypass group; therefore 116
patients were included in the final analysis (Fig. 2). All
patients were operated within 6 weeks of randomization.
The randomization was conducted in a 2.5-year period. The
first 6 months only the St. Antonius Hospital had been
authorized to randomize patients and included 13 patients.
The first year thereafter the St. Antonius Hospital included
19 patients, the University Medical Centre 22 patients, the
Albert Schweitzer Hospital 15 patients, and the Amphia
Hospital 2 patients. The last year of the study the inclusion
was 17, 18, 7 and 3 patients respectively.
Baseline characteristics of the study population are
summarized in Table 1.
Despite randomization, significantly more patients
scheduled for bypass surgery had a single vessel runoff and
consequently more severe symptoms than patients sched-
uled for RSFAE. The bypass group had more patients with
a history of TIA or stroke, and the RSFAE group had more
smokers and more patients with hypercholesterolemia.
Intraoperative results
Intraoperative results are reported in Table 2. Operation
time and blood loss were not statistically different between
groups. The mean length of the endarterectomized intima
core was 30 cm (range, 20e44 cm). Only 25 patients (45%)
in the bypass group had a sufficient saphenous vein suitable
Table 1 Baseline characteristics of study populationa
Variable RSFAE (nZ 61) Bypass (nZ 55) P-valueb
Age, mean (range) y 68 (50e84) 68 (44e86) 0.801
Sex
Male 47 (77) 40 (73) 0.591c
Female 14 (23) 15 (27)
Indication for operation
Rutherford category 3 47 (77) 30 (55) 0.025c
Rutherford category 4 7 (12) 14 (25)
Rutherford category 5 7 (11) 11 (20.0)
Initial claudication distance, mean (range) m 82 (5e300) 81 (0e500) 0.407
ABI, mean (SD) 0.62 (0.14) 0.58 (0.15) 0.185
Treadmill test, mean (SD) 0.32 (0.21) 0.34 (0.22) 0.759
Previous ipsilateral procedures
Central 8 (13) 7 (13) 0.950c
Iliacal 8 (13) 8 (15) 0.823c
Femorald 11 (18) 18 (33) 0.068c
Risk factors
Coronary artery disease 29 (48) 23 (42) 0.536c
Diabetes 15 (25) 9 (17) 0.297c
Stroke or TIA 13 (21) 21 (38) 0.046c
Hypertension 45 (74) 36 (66) 0.330c
Hypercholesterolemia 49 (82) 34 (64) 0.035c
Serum creatinine, mean (SD) mmol/L 105 (49) 109 (125) 0.210
BMI, mean (SD) kg/m2 27 (3.3) 26 (3.8) 0.644
Contralateral amputation 1 (2) 1 (2) 0.941c
Smoking, current or recent 52 (91) 35 (75) 0.021c
Preoperative occlusion of SFA 56 (91) 52 (95) 0.561c
Length of SFA occlusion, mean (range) cm 24 (19e30) 24 (20e28) 0.901
Runoff arteries
1 3 (5) 9 (16) 0.018c
2 15 (25) 18 (33)
3 43 (70) 28 (51)
Preoperative medication
Statin 47 (78) 29 (55) 0.008c
Acetylsalicylic acid 45 (74) 40 (73) 0.899c
Coumarin 16 (26) 10 (18) 0.299c
Clopidogrel 3 (5) 2 (4) 0.734c
Dipyridamole 3 (5) 6 (11) 0.228c
No anticoagulant 2 (3) 4 (7) 0.332c
a Data are presented as No.(%), unless otherwise indicated.
b ManneWhitney U test, unless otherwise indicated.
c c2 test.
d PTA of the SFA without stent placement.
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graft. Initial technical success was 92% in the endarterec-
tomy group versus 100% in the bypass group. Reasons for
conversion in the RSFAE group were perforation of the SFA
during endarterectomy (nZ 3), dissection distally from the
transaction zone (nZ 1), or heavy calcification (nZ 1).
These patients received either an above-knee PTFE bypass
(3 patients, all with perforation) or a below-knee PTFE
bypass (2 patients). During the operation, distal throm-
boemboli were found in 4 RSFAE patients, and all weresuccessfully treated with embolectomy during the
procedure.
Postoperative data
Postoperative data are reported in Table 3. Postoperative
haemorrhage occurred in 5 RSFAE patients (1 requiring
reoperation) and in 4 bypass patients (3 reoperations).
Superficial wound infection was observed in 9 RSFAE patients
and 4 bypass patients, all treated with oral or intravenous
118 patients  
randomized to treatment 
239 patients exluded 
- 17 patients with Rutherford category 4-5 unfitt for surgery 
- 120 patients with Rutherford category 3 treated conservatively 
- 102 patients not meeting inclusion criteria 
†
0 patients lost to follow-up 
1 patient violated inclusion criteria
1 patient unfitt for surgery§
61 patients assigned to RSFAE 
357 patients with a TASC C or 
D lesion of the SFA assesed 
for eligibility 
57 patients assigned to bypass 
0 patients lost to follow-up  
55 patients analysed 61 patients analysed 
Figure 2 Trial profile. yThe occlusion of the SFA in this patient extended below the level of the knee in spite of earlier review of
the MRA as ‘patent popliteal artery’. xThis patient suffered from a myocardial infarction and was considered unfit for surgery.
72 S.S. Gisbertz et al.antibiotics. Three RSFAE patients versus 4 bypass patients
sustained a deep wound infection requiring surgical
debridement. No association could be determined between
post-operatively infection rate and Rutherford classifica-
tion. Explantation of an infected PTFE bypass was necessary
in 1 patient. Median hospital stay was significantly shorter
for RSFAE: 4 days (range 1e21 days) versus 6 days (range 3e
28 days; pZ 0.004), whereas re-admittance differed not
statistically significant between the two groups.
(Re)occlusion within 30 days occurred in 3 RSFAE
patients and 2 bypass patients. Of the 3 RSFAE patients,
1 patient had only mild claudication symptoms (RutherfordTable 2 Intraoperative resultsa
Variable RSFAE (
Operation time, mean (SD) min 134 (32
Blood loss, mean (SD) mL 270 (18
Intima core, mean (range) cm 30 (20
aSpire stent
Length, median (range) cm 5 (5e
Diameter, median (range) mm 7 (5e
Graft
Venous
Prosthetic
Additional procedure
None 6 (10
Common femoral and/or profundaplasty 49 (80
Iliacal PTA or remote endarterectomy 5 (8)
Popliteal PTA or remote endarterectomy 1 (2)
Patch closure 50 (89
a Data are presented as No.(%), unless otherwise indicated.
b ManneWhitney U test, unless otherwise indicated.
c c2 test.category 2) and no reintervention was necessary, 1 patient
received an infragenicular bypass, and 1 early reocclusion
occurred in a RSFAE patient with a primary conversion (due to
heavy calcification) to an infragenicular bypass. No vascular
reconstruction could be performed, and below-knee amputa-
tion was necessary. The initial indication for this operationwas
gangrene (Rutherford category 5). The two patients in the
bypass group with early occlusion were both successfully
treated with thrombectomy. One patient in the bypass group
was readmitted with persistent ischemia and underwent PTA
of thepopliteal artery andpartial foot amputation. Noneof the
patients died in the hospital or within 30 days after operation.nZ 61) Bypass (nZ 55) P-valueb
.6) 125 (32.6) 0.159
6.7) 208 (150.5) 0.092
e44)
15)
8)
25 (45)
30 (55)
) 6 (14) 0.755c
) 46 (80)
2 (4)
1 (2)
)
Table 3 Postoperative dataa
Variable RSFAE (nZ 61) Bypass (nZ 55) P-valueb
Postoperative haemorrhage 5 (8) 4 (7) 0.257
Superficial wound infection 9 (15) 4 (7) 0.202
Deep wound infection 3 (5) 4 (7) 0.595
Pneumonia 1 (2) 1 (2) 0.941
Urinary tract infection 2 (3) 2 (4) 0.916
Postoperative renal failured 0 (0) 0 (0)
Oedema 9 (15) 13 (24) 0.223
Seroma 6 (10) 5 (9) 0.891
ABI, mean (SD) 0.90 (0.18) 0.92 (0.23) 0.945c
Hospital stay, median (range) days 4 (1e21) 6 (3e28) 0.004c
Re-admittance 6 (10) 7 (13) 0.622
Early reocclusion (<30 days) 3 (5) 2 (4) 0.734
a Data are presented as No.(%), unless otherwise indicated.
b c2 test, unless otherwise indicated.
c ManneWhitney U test.
d Defined as a >20% decrease in serum creatinine clearance compared to baseline, the presence of new-onset dialysis, or both.
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Mean follow-up was 12 months in both groups. Primary
patency rate after 1 year of follow-up was 61% for RSFAE
and 73% for femoropopliteal bypass (pZ 0.094). Assisted
and primary patency rates were 73% and 75%, respectively
(pZ 0.698). Secondary patency was 79% for both groups
(pZ 0.953; Figs. 3e5). Limb salvage was 98%, with 1 major
below-knee amputation performed in both groups. Sub-
dividing between venous and prosthetic grafts shows
primary patency rates of 89% and 63%, respectively,
compared with 61% for RSFAE (pZ 0.086), assisted primary
patency rates of 94% and 63% compared with 73%
(pZ 0.104), and secondary patency rates of 94% and 63%
compared with 79% (pZ 0.137) at 1 year of follow-up.
Treatment of the 15 reoccluded SFA’s in the RSFAE group
and the 8 occluded bypasses in the bypass group is shown in
Fig. 6. Of the 9 restenoses in the RSFAE group, 8 were
treated with PTA, and 1 was treated with endarterectomy
of the femoral bifurcation. Restenosis was equally distrib-
uted within the SFA and was not restricted to the stent. Of
the 2 stenoses in the bypass group, 1 was treated with PTA
and the other had multiple stenoses and was reoperated on
with a proximal patch plasty and a distal bypass jump graft
to maintain patency. Stenosis in the graft was not limited to
the anastomoses.
At 1-year follow-up, 5 patients had died: 4 (7%) in the
RSFAE group and 1 (2%) in the bypass group. One death in
the RSFAE group was related to the operation. This patient
developed a saccular aneurysm of the common femoral
artery (not mycotic) and underwent endovascular stent
placement. This operation was complicated by recurrent
septic bleeding, and the patient eventually died.
Influence of risk factors
Univariate analysis revealed that primary patency survival
in the RSFAE group was not influenced by BMI, serum
creatinine level, runoff, previous vascular procedures on
target leg, medication, diabetes, hypertension andhypercholesterolemia, coronary artery disease, stroke or
TIA, age and smoking. Sex and indication for operation
showed an association with the primary patency (p< 0.10)
and were consequently analysed in a Cox hazard regression
model. Multivariate analysis showed only female gender as
a significant predictor of reocclusion and restenosis with
a hazard ratio of 3.47 (95% CI 1.17e10.35; pZ 0.025). For
the bypass group, no independent risk factors influencing
patency could be determined.
Discussion
This report describes the short-term results of the first
randomized trial between RSFAE and supragenicular femo-
ropopliteal bypass for TASC C and D lesions of the SFA.
Although not significant, the trial results show a difference
in primary patency rates in favour of bypass. The assisted
primary and secondary patency rates, however, are
comparable in both groups. Subdividing between vein and
prosthetic grafts shows superiority for vein, with compa-
rable primary patency rates for RSFAE and prosthetic
grafts. In only 45% of patients scheduled for bypass surgery
could the ipsilateral greater saphenous vein be used. A
study by Johnson and Lee found that 11% of patients lacked
a sufficient saphenous vein, excluding these used for
previous cardiac procedures.7 The role of preoperative
venous mapping as a possible application in the preopera-
tive decision-making, needs to be addressed further.
In the postoperative course, there were no statistically
significant differences in complications between the
2 groups, although 1 patient required explantation of an
infected PTFE bypass. Hospital stay, on the other hand,
was significantly shorter for RSFAE: 4 versus 6 days
(pZ 0.004).
Our study has several limitations. Despite randomiza-
tion, significantly more patients with critical ischemia were
allocated to the bypass group. In addition, more patients in
the bypass group presented with a single vessel runoff. It is
well established that patients presenting with claudication
perform better, although this could not be demonstrated in
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Figure 3 KaplaneMeier survival estimate comparing primary
patency of remote superficial femoral artery endarterectomy
(RSFAE) with suprageniculate femoropopliteal bypass
(Log-Rank test: pZ 0.094).
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Figure 5 KaplaneMeier survival estimate comparing
secondary patency of remote superficial femoral artery
endarterectomy (RSFAE) with suprageniculate femoropopliteal
bypass (Log-Rank test: pZ 0.953).
74 S.S. Gisbertz et al.this trial.5,6,17 There were more differences between the 2
groups in baseline characteristics, with significantly more
current or recent smokers and patients with hypercholes-
terolemia in the bypass group but fewer patients with
a history of stroke or TIA. When we assessed this imbalance
by use of Cox Hazard regression analysis, the adjusted
patency rates remained unchanged (data not shown).
Initial technical success of the RSFAE group was high,
with only 5 conversions to bypass; however, compared with
recent literature, our results show a lower primary patency
for RSFAE than expected. A recent report by Martin et al.Time (months)
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Figure 4 KaplaneMeier survival estimate comparing assisted
primary patency of remote superficial femoral artery endar-
terectomy (RSFAE) with suprageniculate femoropopliteal
bypass (Log-Rank test: pZ 0.698).showed a primary patency rate of 70% at 30 months.18
Knight et al. described an 84% primary patency rate at
18 months compared with 62% at the 1-year follow-up in our
trial.19 Other authors show less favourable results for
RSFAE: Ali et al. reached a primary patency of only 42%
after RSFAE in combination with covered endografts at 12
months20; however, this study population consisted of only
18 patients. Rosenthal et al. performed a retrospective
multicenter analysis of 40 patients treated with RSFAE,
resulting in a primary patency rate of 69% at 18 months, and
from the same authors, a multinational retrospective
analysis among 210 patients revealed a primary patency of
61% at 33 months.11,13 Our results for bypass surgery are
consistent with recent literature, with associated primary
patency rates reaching 57e83% at 1 or 2 years of follow-up,
depending on the used graft, with superior results for
autologous vein.2,5e10
This is however, an interim report, long-term results will
have to prove durability of both procedures.
A possible explanation for the lower primary patency in
the RSFAE group could be the prospective setting, in an
unselected population. Remarkable in the present study is
the high percentage of smokers, with current or recent
smoking in 91% of patients allocated to RSFAE. The present
RSFAE study population shows significant comorbidity, with
48% coronary artery disease, 25% diabetes, 21% history of
stroke or TIA, 82% hypercholesterolemia, and 74% hyper-
tension. Although the difference with other study pop-
ulations is marked, an independent relation affecting
patency could not be demonstrated here.17,18,21 In our
series, regression analysis revealed no independent risk
factors predicting failure, besides female gender, influ-
encing primary patency in the RSFAE group, with a hazard
ratio of 3.47 (95% CI 1.17e10.35; pZ 0.025). Female gender
as an independent risk factor has not been shown previously.
An explanation could be the smaller diameter of the SFA in
women, although we have no data to support this.
15 reocclusions
(including 3 early reocclusions)
6 infrageniculate bypass
(3 venous, 3 PTFE)
1 suprageniculate bypass and thrombolysis
1 below-knee amputation
1 expectantly (mild symptoms)
2 suprageniculate bypass
(1 venous, 1 PTFE)
3 PTA 3 thrombolysis
1 infrageniculate bypass
(vein)
1 suprageniculate bypass
(vein) and PTA
1 expectantly
8 occlusions
(including 2 early occlusions)
1 infrageniculate bypass 
(venous)
3 thrombectomy 3 thombolysis 1 PTA
1 suprageniculate bypass
(PTFE)
2 thrombolysis
1 PTA and infrageniculate bypass (vein)
1 profundaplasty with patch closure
1 expectantly (mild symptoms)
2 infrageniculate bypass
(1 venous, 1 PTFE)
a
b
Figure 6 a. Treatment of reoccluded SFA’s after RSFAEx. b. Treatment of occluded bypasses. xThe interventions after (re)
occlusion are displayed in the 1st row below the (re)occlusions. The 2nd row shows treatment after failure of reintervention.
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presumed aggressive neointimal hyperplasia remains the
Achilles heel of the RSFAE procedure, with 83% of restenosis
detected within 1 year.15 After the first year, the restenosis
rate declines and is thought to be caused by progression of
atherosclerosis rather than neointimal hyperplasia.15
Therefore, future prevention of neointimal hyperplasia
seems to be the key to successful preventing restenosis
progressing to reocclusion. Recent research is focussing on
this subject, with the development of gene and drug
therapy, cryotherapy, drug eluting stents, endothelial cell
seeding, and radiation or brachytherapy. A recent
randomized trial by Tepe et al. showed promising results
with balloon catheters for PTA coated with Paclitaxel. They
found significantly less lumen reduction at 6 months and
a remarkable lower reintervention rate at 6 and 24 months
of 4% and 15%, respectively, for the Paclitaxel group versus
37% and 52% for the control group.22 Perhaps results will
improve after surgically debulking the SFA, which leaves
the proliferative cells bare and therefore possibly more
sensitive to drug treatment.
The role of cryoplasty is not yet defined, with conflicting
results and no randomized trials performed so far.23 Karthik
et al. described a 100% restenosis rate within 1 year after PTA
with additional cryoplasty for recurrent stenoses, but again,
surgically debulking the SFA might improve outcome.24
Graft material for bypasses is evolving as well. Heparin-
bonded Dacron grafts have been introduced to bypass the
SFA, with better outcome compared with PTFE. Differences
in patency rates were not significant at 5 years of follow-
up, but limb salvage was 86% for heparin-coated Dacron
versus 74% for PTFE.5RSFAE is a minimal invasive adjunct in the treatment of
chronic long occlusions of the SFA, with significantly shorter
hospital stay and comparable assisted primary and
secondary patency rates to bypass surgery. However, the
venous bypass is superior to both RSFAE and prosthetic
bypass grafts, but only 45% of patients had a sufficient
saphenous vein available. For patients lacking the saphe-
nous vein, RSFAE could be the procedure of choice because
prosthetic material can be avoided.
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